Policy
Health Care’s second-half 2026 rally has largely been a defensive rotation, not the start of a new bull market. Health Care leadership is more typical when the economy is slowing/contracting and is hard to sustain in a rising market. With the cycle still firm and our expectation that the market rallies into year end, we are neutral on the sector, though we recognize its hedging value. Within Health Care, we are underweight Providers & Services, overweight Equipment & Supplies, and market weight Pharmaceuticals, Biotech & Life Sciences (“Pharma”).
AI capex concerns have pushed the S&P 500 to the brink of a drawdown. But the cycle remains strong, drawdowns rarely last long, and Tech valuations had already compressed. And while Democratic governors now oversee about 80% of the data-center pipeline, a blue governor alone is not necessarily a build-out moratorium.
The Fed will hike rates at a pace of 25 bps per quarter until either falling inflation or tighter financial conditions cause it to stop.
Democrats will win both houses in the midterm, but beyond near-term volatility, none of the outcomes pose a major market risk. The vote is more important as a signal of an anti-business turn in US policy in coming years, which markets could start to price in late 2027 or early 2028.
Core US inflation is still running above target. But this morning’s data revisions reveal that the gap is not nearly as large as it appeared yesterday.
The Fed is unanimous in expecting a mild tightening cycle of no more than 75 bps, but that outcome is contingent on a rapid drop in core inflation in 2027.

